Nuvation Bio
NUVB
4.86
-0.02
-0.41%
Nuvation Bio
US · NUVB
#2898 by market cap
Listed 1970
4.86
-0.02
-0.41%
Live - 5344 symbols - heartbeat 421s ago
· 2026-10-08 06:15
Pre-market
4.92
+1.23%
After-hours
4.95
+1.85%
Overnight
4.82
-0.82%
- Market cap
- 1.71B
- P/E (TTM)i
- -11.05
- P/Bi
- 6.72
- EPSi
- -0.60
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on NUVB?
Anonymous reader poll. Unscientific, not investment advice.
About Nuvation Bio
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
- Founded
- 2018
- CEO
- Dr. David T. Hung,M.D.
- Employees
- 298
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- nuvationbio.com
Company profile
- Exchange
- US
- Symbol
- NUVB
- Market-cap rank
- #2898
- Listing date
- 1970-01-01
- Market cap
- 1.71B
- Float cap
- 1.28B
- Shares out
- 351.12M
- Float shares
- 263.65M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 06:15:32 · For reference only, not investment advice and not tailored to your situation.